USA-based DOV Pharmaceuticals says that Leslie Hudson has resigned as president, chief executive and board member, and that his posts as president and board member have been taken up by current chief financial officer Barbara Duncan. Also, the firm's
chief scientific officer, Phil Skolnick, has been named executive vice president and CSO, current chairman Arnold Lippa is now executive chairman of the board. The moves are aimed at maximizing DOV's existing pipeline and to "explore and pursue" its "most attractive financing opportunities."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze